Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Oncology
2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
ZanubrutinibPhase 2Small Molecule1 trial
Active Trials
NCT04116437CompletedEst. Jan 2026
TG Therapeutics
TG TherapeuticsNEW YORK, NY
1 program
1
TGR-1202Phase 11 trial
Active Trials
NCT02268851CompletedEst. Oct 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BeOne MedicinesZanubrutinib
TG TherapeuticsTGR-1202

Clinical Trials (2)

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Start: Oct 2019Est. completion: Jan 2026
Phase 2Completed

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Start: Nov 2014Est. completion: Oct 2022
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space